Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

August 24, 2022

Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications

ACS Fall 2022
Other
Read More
June 26, 2022

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology

37th ACS National Medicinal Chemistry Symposium
Other
Read More
June 7, 2022

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Targeting protein degradation 3 – from discovery to the clinic (TPD3)
Other
Read More
June 1, 2022

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Other
Read More
June 1, 2022

Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Other
Read More
April 7, 2022

KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)

American Association for Cancer Research Annual Meeting
Other
Read More
December 13, 2021

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

The 63rd Annual ASH Meeting and Exposition
Other
Read More
December 13, 2021

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

The 63rd Annual ASH Meeting and Exposition
Other
Read More
November 12, 2021

Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition

SITC 2021
Other
Read More
October 27, 2021

Understanding PK/PD for Development of STAT3 Degraders in Oncology Indications

4th Annual TPD Summit
Other
Read More